Table 1

Baseline features and results

All patient eyesStratified by anti-VEGF medicationStratified by baseline VA
AfliberceptBevacizumabRanibizumab20/40 or better20/40 to 20/7020/70 to 20/20020/200 or worse
Patient eyes
n28 658645915 273692610 585963359392469
%1002353243734219
Gender (%)
Male5354525455535149
Female4746484645474951
Mean age (years)62.163.161.163.460.963.36361.2
Mean number of injections in 1 year6.46.36.36.76.16.66.66.1
Mean VA (letters)
Baseline VA59.260.357.96175.663.547.41.2
Change at 1 year+4.2+4.3+4.5+3.4−2.2+2.0+6.7+34.2
Final VA63.464.662.464.473.465.554.135.4
P value<0.001<0.001<0.001<0.001<0.001<0.001<0.001<0.001
95% CI4.0 to 4.53.9 to 4.84.2 to 4.93.0 to 3.9−2.7 to −2.11.7 to 2.36.2 to 7.333.4 to 36.8
  • anti-VEGF, antivascular endothelial growth factor; VA, visual acuity.